MET and neoplasm: c-Met/PD-1 CAR-T cells block the interaction between PD-1 and PD-L1, displaying lower levels of inhibitory receptors, reduced differentiation, enhanced anti-tumor activity, and extended survival compared to conventional CAR-T cells (92).